< Back to previous page
Researcher
Sofie Deschoemaeker
- Keywords (Vrije Universiteit Brussel):Applied biological sciences, biotechnology
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Adaptive immunology, Bacteriology
- Disciplines (Vrije Universiteit Brussel):Innate immunity, Cancer therapy
Affiliations
- Brussels Center for Immunology (Research group)
Member
From1 Jan 2023 → Today - Brussels Center for Immunology (Research group)
Member
From1 Jan 2024 → 30 Sep 2025 - LAOUI LAB (Research group)
Member
From1 Oct 2022 → Today - FORMER_Cellular and Molecular Immunology (Research group)
Member
From1 Jan 2021 → 30 Sep 2022 - Department of Bio-engineering Sciences (Department)
Member
From1 May 2020 → 30 Sep 2025 - Department of Bio-engineering Sciences (Department)
Member
From1 May 2020 → 31 Dec 2020 - FORMER_Cellular and Molecular Immunology (Research group)
Member
From15 Jan 2020 → 31 Dec 2023 - FORMER_Cellular and Molecular Immunology (Research group)
Member
From15 Jan 2020 → 20 Oct 2022 - VAN GINDERACHTER LAB (Research group)
Member
From15 Jan 2020 → 30 Sep 2022
Projects
1 - 1 of 1
- Towards the rational design of cancer therapies combining tumorderived dendritic cell vaccinations with regulatory TFrom1 Nov 2022 → TodayFunding: FWO fellowships
Publications
1 - 10 of 11
See also Sofie Deschoemaeker for publications of Flanders Institute for Biotechnology.
Here below the publications of Vrije Universiteit Brussel.
- Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity(2024)Published in: NATURE COMMUNICATIONSISSN: 2041-1723Issue: 1Volume: 15
- Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models(2023)Published in: Frontiers In ImmunologyISSN: 1664-3224Volume: 14Pages: 1-11
- Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer(2022)Published in: Cancers (Basel)ISSN: 2072-6694Issue: 16Volume: 14
- Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions(2022)Published in: Int. J. Mol. Sci.ISSN: 1661-6596Issue: 2Volume: 23
- Heterogeneity and function of macrophages in the breast during homeostasis and cancer(2022)Series: International Review of Cell and Molecular BiologyPages: 149-182Number of pages: 34
- Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506(2021)Published in: Mol. Cancer Ther.ISSN: 1535-7163Issue: 12Volume: 20Pages: 2372-2383
- IFNγ signaling response in peripheral blood monocytes: A new prognostic biomarker for breast cancer?(2020)Published in: EBioMedicineISSN: 2352-3964Volume: 53Pages: 102690
- Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models.(2018)Published in: J. Cell. Mol. Med.ISSN: 1582-1838Issue: 3Volume: 23Pages: 1908-1916
- The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1α Levels and Colorectal Cancer Cell Survival under Hypoxia(2017)Published in: Cell ReportsISSN: 2211-1247Issue: 7Volume: 18Pages: 1699-1712
- Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity(2012)Published in: Cancer CellISSN: 1535-6108Issue: 2Volume: 22Pages: 263-277